AcQBlate Force Sensing Ablation System US IDE Study for Atrial Fibrillation

Paroxysmal Atrial Fibrillation Clinical Trial

— AcQForce AF  

Official title:

AcQBlate Force Sensing Ablation System US IDE Study for Atrial Fibrillation (AcQForce AF)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04904354
• Other study ID #: CLP-16
• Secondary ID: CLP-16-EU
• Status: Withdrawn
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: December 1, 2025

Study information

• Verified date: November 2023
• Source: Acutus Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The AcQForce AF clinical study is a prospective, multi-center, non-randomized global clinical study.

Description:

The AcQForce AF clinical study is a prospective, multi-center, non-randomized global clinical study designed to demonstrate the safety and efficacy of the AcQBlate Force Sensing System in the ablation treatment of symptomatic, drug-refractory atrial fibrillation in two subject cohorts: paroxysmal atrial fibrillation, and persistent atrial fibrillation. Data will be used to support pre-market approval applications (PMAs).

Other known NCT identifiers

• NCT04941391

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 1, 2025
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female between the ages of 18 to 80 years at time of consent

2. Clinically indicated and scheduled for a de novo catheter ablation of symptomatic PAF or PerAF.

3. Refractory to Antiarrhythmic Drug (AAD) treatment

4. Willing and able to provide written informed consent to participate in the study and agree to comply with all follow-up visits and evaluations for the duration of the study.

Exclusion Criteria:

1. In the opinion of the investigator, any contraindication to the planned atrial ablation, including anticoagulation contraindications or sepsis.

2. Continuous episodes of AF Duration:

1. PAF: AF duration lasting longer than 7 days

2. Persistent AF: AF duration lasting longer than 12-months.

3. Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause.

4. An implantable cardiac defibrillator (ICD) or pacemaker.

5. Previous history of left atrial ablation (including surgical treatment) for AF/AT/AFL.

6. Structural heart disease or cardiac history as described below:

1. Left ventricular ejection fraction (LVEF) < 40% based on transthoracic echocardiogram (TTE) within the previous 180-days.

2. Left atrial size > 55 mm based on transthoracic echocardiogram (TTE) measurement of the anteroposterior diameter, parasternal long-axis view in M Mode and performed within the previous 180-days.

3. Evidence of heart failure (NYHA Class III or IV)

4. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for coronary artery bypass).

5. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve.

6. Coronary artery bypass graft (CABG) within the last 180-days or coronary angioplasty (PTCA) procedure within the last 90-days.

7. Unstable angina or ongoing myocardial ischemia.

8. Myocardial infarction within the previous 180-days (sub-endocardial infarct within previous 90-days).

9. Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg, diastolic pressure > 140 mm Hg) recorded within the last 30 days.

10. Moderate or severe valvular heart disease (stenosis or regurgitation).

11. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder.

12. Presence of a left atrial appendage occlusion device.

13. Previous PV stenting or evidence of PV stenosis.

7. Presence of Left Atrial Thrombus

8. Body Mass Index (BMI) > 42 kg/m2

9. Estimated Glomerular Filtration Rate (eGFR) of <40 mL/min/1.73 m2 (by Modification of Diet in Renal Disease formula)

10. History of blood clotting or bleeding disease.

11. ANY prior history of documented cerebral infarct, or systemic embolism (excluding post-operative deep vein thrombosis (DVT)).

12. History of chronic obstructive pulmonary disease (COPD) requiring oral or IV steroid use in the previous 12-months.

13. History of obstructive sleep apnea not currently being treated.

14. Pregnant or lactating (current or anticipated during study follow-up).

15. Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study.

16. Any other condition that, in the judgment of the Investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center).

Related Conditions & MeSH terms

• Atrial Fibrillation
• Paroxysmal Atrial Fibrillation
• Persistent Atrial Fibrillation

Intervention

Device:
• AcQBlate® Force Sensing Ablation System
Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Acutus Medical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjects who are free from device and/or procedure related Major Adverse Events (MAEs)	Subjects free from a composite list of pre-specified procedure/device related Major Adverse Events (MAEs)	12 months
Primary	Proportion of subjects demonstrating freedom from AF/AT/AFL following a blanking period	Freedom from recurrence of atrial arrhythmias	12 months
Secondary	Recording of all serious adverse events/device effects	Recording of all serious adverse events/device effects	12 months